DocGo Inc (DCGO)vsEli Lilly and Company (LLY)
DCGO
DocGo Inc
$0.49
-1.91%
HEALTHCARE · Cap: $54.93M
LLY
Eli Lilly and Company
$1,208.12
+7.13%
HEALTHCARE · Cap: $1.08T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 23846% more annual revenue ($72.25B vs $301.71M). LLY leads profitability with a 35.0% profit margin vs -62.2%. LLY earns a higher WallStSmart Score of 78/100 (B+).
DCGO
Hold36
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+53.4%
Fair Value
$1.56
Current Price
$0.49
$1.07 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -141.9% — below average capital efficiency
Revenue declined 21.3%
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 34.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : DCGO
The strongest argument for DCGO centers on Price/Book, Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : DCGO
The primary concerns for DCGO are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.9x leaves little room for execution misses.
Key Dynamics to Monitor
DCGO profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
DCGO carries more volatility with a beta of 1.00 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 36/100), backed by strong 35.0% margins and 55.5% revenue growth. DCGO offers better value entry with a 53.4% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DocGo Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DocGo Inc. is an innovative mobile healthcare service provider that enhances patient access and optimizes healthcare delivery through its advanced logistics and telehealth solutions. Specializing in urgent care, diagnostic testing, and health screenings, DocGo addresses critical healthcare needs across various settings while significantly improving patient experiences. With a commitment to innovation and expanding healthcare accessibility, the company stands out in the rapidly evolving healthtech sector, positioning itself as a compelling investment opportunity for institutional investors seeking both sustainable growth and positive social impact.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?